Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

2(66.7%)

Phase 3

1(33.3%)

3Total

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04635891Recruiting

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Role: collaborator

NCT07486934Phase 3Recruiting

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Role: lead

NCT03458832Active Not Recruiting

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Role: collaborator

NCT05481879Phase 1Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Role: lead

NCT05524883Phase 1Active Not Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Role: lead

All 5 trials loaded